FAIRMOUNT PARTNERS ADVISES PINNACLE 21 IN ITS PENDING ACQUISITION BY CERTARA

Expected to Close in Early Q4 of 2021

 

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced it has signed a definitive agreement to acquire Pinnacle 21 for $310 million in cash and stock.  Pinnacle 21’s software tools are used to validate compliance to the Clinical Data Interchange Standards Consortium (CDISC) standards, which is required by the US FDA and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for drug submissions and preferred by China’s National Medical Products Administration (NMPA).

READ THE PRESS RELEASE
Pinnacle21_PendingAcquisitionBy_Certara.png